15 studies found for:    BMS-663513
Show Display Options
Download search resultsDownload the search results for:
BMS-663513 (15 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Completed Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Condition: Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma
Intervention: Drug: Urelumab (BMS-663513)
2 Active, not recruiting Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma
Condition: B-Cell Malignancies
Interventions: Biological: Urelumab;   Biological: Rituximab
3 Active, not recruiting A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Elotuzumab;   Drug: Lirilumab;   Drug: Urelumab
4 Terminated A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC)
Condition: Non Small Cell Lung Cancer
Intervention: Drug: BMS-663513
5 Terminated A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies
Condition: Advanced Solid Malignancies
Intervention: Drug: BMS-663513
6 Active, not recruiting Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
Conditions: Colorectal Cancer;   Head and Neck Cancer
Interventions: Biological: Urelumab;   Biological: Cetuximab
7 Not yet recruiting Neoadjuvant Nivolumab With and Without Urelumab in Patients With Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma of the Bladder
Conditions: Urothelial Carcinoma;   Bladder Cancer
Interventions: Drug: Nivolumab in combination with Urelumab;   Drug: Urelumab monotherapy
8 Recruiting Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors
Condition: Malignant Tumors
Interventions: Drug: Urelumab;   Drug: Nivolumab
9 Recruiting Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkins Lymphoma
Conditions: Advanced Solid Tumors;   Advanced B-cell NHL
Interventions: Biological: Urelumab;   Biological: Nivolumab
10 Terminated Study of BMS-663513 in Patients With Advanced Cancer
Condition: Tumors
Intervention: Drug: BMS-663513
11 Recruiting Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients
Condition: Leukemia
Interventions: Drug: Rituximab;   Drug: Urelumab
12 Withdrawn Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma
Condition: Melanoma
Interventions: Drug: AntiCD137;   Drug: Ipilimumab
13 Completed Phase II, 2nd Line Melanoma - RAND Monotherapy
Condition: Melanoma
Intervention: Drug: Anti-CD137 (4-1BB) (BMS-663513)
14 Not yet recruiting Anti-LAG-3 or Urelumab Alone and in Combination With Nivolumab in Treating Patients With Recurrent Glioblastoma
Conditions: Glioblastoma;   Gliosarcoma;   Recurrent Brain Neoplasm
Interventions: Biological: Anti-LAG-3 Monoclonal Antibody BMS 986016;   Biological: Anti-PD-1;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis;   Biological: Anti-CD137
15 Recruiting Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma
Conditions: Melanoma (Skin);   Skin Cancer
Interventions: Drug: Nivolumab;   Procedure: Surgery to Remove Tumor for Growth of TIL;   Drug: CD137;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: TIL Infusion;   Drug: Interleukin-2

Indicates status has not been verified in more than two years